56813-54-8

Basic information

• Product Name: 1,2,4-Triazolo[3,4-a]phthalazine, 6-chloro-3-phenyl-
• CAS NO: 56813-54-8
• Molecular Formula: C15H9ClN4
• Molecular Weight: 280.716
• Mol File: 56813-54-8.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 1,2,4-Triazolo[3,4-a]phthalazine, 6-chloro-3-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Triazolo[3,4-a]phthalazine, 6-chloro-3-phenyl-(56813-54-8)
• EPA Substance Registry System: 1,2,4-Triazolo[3,4-a]phthalazine, 6-chloro-3-phenyl-(56813-54-8)

Safety Data

• Hazardous Substances Data: 56813-54-8(Hazardous Substances Data)

Usage

Structure

Phthalazine derivative with a triazolopyridazine ring system and a phenyl group

Potential applications

a. Anti-cancer agent
b. Ligand for various biological targets

Significance

Unique structure and molecular properties make it an interesting subject for further research and development in medicinal chemistry and drug discovery.

Upstream product

• 51935-42-3 4-chloro-1-phthalazinone hydrazone 
• 15424-14-3 N-phenylbenzohydrazonoyl chloride 
• 64640-64-8 2-methyl-4-chloro-1-phthalazinone hydrazone 
• 56813-52-6 4-chloro-1-phthalazinone benzylidenehydrazone 
• 56813-52-6 benzaldehyde (4-chloro-phthalazin-1-yl)-hydrazone 
• 6145-55-7 4-hydrazino-1-chlorophthalazine hydrochloride 
• 98-88-4 benzoyl chloride 
• 51935-42-3 1-chloro-4-hydrazinophthalazine 
• 100-52-7 benzaldehyde 
• 144-55-8 sodium hydrogencarbonate 
• 4752-10-7 1,4-dichlorophthalazine 
• 85-44-9 phthalic anhydride 
• 1445-69-8 2,3-dihydrophthalazine-1,4-dione 

Downstream Products

• 87539-84-2 3-phenyl-6-(1-pyrrolidinyl)-1,2,4-triazolo[3,4-a]phthalazine 
• 87539-98-8 3-phenyl-6-piperidinyl-1,2,4-triazolo[3,4-a]phthalazine 
• 87540-01-0 N-ethyl-N-methyl-3-phenyl-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 87540-40-7 6-ethoxy-3-phenyl-1,2,4-triazolo[3,4-a]phthalazine 
• 87539-89-7 3-Phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamine 
• 87539-96-6 3-phenyl-N,N-dimethyl-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 87539-92-2 Isopropyl-(3-phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-amine 
• 113628-67-4 Butyl-(3-phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-amine 
• 87539-90-0 Methyl-(3-phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-amine 
• 87539-93-3 Benzyl-(3-phenyl-[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-amine 
• 87540-64-5 6-ethanethiol-3-phenyl-1,2,4-triazolo<3,4-a>phthalazine 

Relevant articles and documents

TRIAZOLOPHTHALAZINE COMPOUNDS, USE AS ANTI-HUMAN IMMUNODEFICIENCY VIRUS INHIBITORS OF HIV VIF-DEPENDENT DEGRADATION OF APOBEC3

The present disclosure is concerned with triazolophthalazine compounds that are capable of inhibiting infection by the Human Immunodeficiency Virus (HIV) by inhibiting HIV Vif-dependent degradation of the APOBEC3 innate immune system. The present disclosu

Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a] phthalazine derivatives

Trying to develop potent and selective anticancer agents, two series of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives were designed and synthesized. Their antitumor activities were evaluated by MTT method against four selected human cancer cell lines (MGC-803, EC-9706, HeLa and MCF-7). Our results showed that compound 11h exhibited good anticancer activities compared to 5-fluorouracil against the four tested cell lines, with IC50 values ranging from 2.0 to 4.5 μM. Flow cytometry analysis indicated that compound 11h induced the cellular early apoptosis and cell cycle arrest at G2/M phase in EC-9706.

TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN

The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.